Found: 92
Select item for more details and to access through your institution.
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
- Published in:
- 2016
- By:
- Publication type:
- corrected article
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Targeted Therapy in Rectal Cancer.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 9, p. 1055
- By:
- Publication type:
- Article
Radiation Therapy for Resectable Colon Cancer.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 2, p. 179
- By:
- Publication type:
- Article
Relative Bioavailability of Pediatric Oral Solution and Tablet Formulations of Trametinib in Adult Patients With Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 4, p. 287, doi. 10.1002/cpdd.152
- By:
- Publication type:
- Article
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1081, doi. 10.1007/s10637-021-01086-6
- By:
- Publication type:
- Article
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 1, p. 163, doi. 10.1007/s10637-020-00975-6
- By:
- Publication type:
- Article
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 1, p. 182, doi. 10.1007/s10637-020-01000-6
- By:
- Publication type:
- Article
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1145, doi. 10.1007/s10637-019-00873-6
- By:
- Publication type:
- Article
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 2, p. 419, doi. 10.1007/s10637-019-00776-6
- By:
- Publication type:
- Article
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 147, doi. 10.1007/s10637-018-0646-1
- By:
- Publication type:
- Article
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 683, doi. 10.1007/s10637-018-0580-2
- By:
- Publication type:
- Article
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 627, doi. 10.1007/s10637-017-0444-1
- By:
- Publication type:
- Article
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 634, doi. 10.1007/s10637-017-0473-9
- By:
- Publication type:
- Article
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 3, p. 298, doi. 10.1007/s10637-016-0420-1
- By:
- Publication type:
- Article
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 2, p. 235, doi. 10.1007/s10637-017-0439-y
- By:
- Publication type:
- Article
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 2, p. 216, doi. 10.1007/s10637-016-0327-x
- By:
- Publication type:
- Article
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 5, p. 1100, doi. 10.1007/s10637-015-0282-y
- By:
- Publication type:
- Article
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 349, doi. 10.1007/s10637-014-0191-5
- By:
- Publication type:
- Article
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 432, doi. 10.1007/s10637-015-0207-9
- By:
- Publication type:
- Article
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 463, doi. 10.1007/s10637-015-0218-6
- By:
- Publication type:
- Article
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 187, doi. 10.1007/s10637-014-0177-3
- By:
- Publication type:
- Article
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-41618-7
- By:
- Publication type:
- Article
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 7, p. 2443, doi. 10.1007/s00262-023-03430-6
- By:
- Publication type:
- Article
Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092240
- By:
- Publication type:
- Article
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2985, doi. 10.3390/cancers12102985
- By:
- Publication type:
- Article
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].
- Published in:
- International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276
- By:
- Publication type:
- Article
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
- Published in:
- International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911
- By:
- Publication type:
- Article
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 670, doi. 10.1007/s10637-014-0082-9
- By:
- Publication type:
- Article
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 682, doi. 10.1007/s10637-014-0088-3
- By:
- Publication type:
- Article
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 700, doi. 10.1007/s10637-014-0089-2
- By:
- Publication type:
- Article
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 87, doi. 10.1007/s10637-013-9949-4
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 927, doi. 10.1007/s10637-012-9900-0
- By:
- Publication type:
- Article
A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 4, p. 1183, doi. 10.1002/cam4.3630
- By:
- Publication type:
- Article
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 11, p. 5148, doi. 10.1002/cam4.2425
- By:
- Publication type:
- Article
Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 11, p. 5382, doi. 10.1002/cam4.1703
- By:
- Publication type:
- Article
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
- Published in:
- PLoS ONE, 2019, v. 14, n. 9, p. 1, doi. 10.1371/journal.pone.0221994
- By:
- Publication type:
- Article
Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
- Published in:
- Cancer (0008543X), 2005, v. 103, n. 9, p. 1925, doi. 10.1002/cncr.21002
- By:
- Publication type:
- Article
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 12, p. 2972
- By:
- Publication type:
- Article
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
- Published in:
- Nature Communications, 2016, v. 7, n. 8, p. 12624, doi. 10.1038/ncomms12624
- By:
- Publication type:
- Article
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
- Published in:
- Clinical Colorectal Cancer, 2023, v. 22, n. 1, p. 100, doi. 10.1016/j.clcc.2022.11.002
- By:
- Publication type:
- Article
Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study.
- Published in:
- Clinical Colorectal Cancer, 2013, v. 12, n. 4, p. 239, doi. 10.1016/j.clcc.2013.09.001
- By:
- Publication type:
- Article
Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2013, v. 12, n. 3, p. 218, doi. 10.1016/j.clcc.2013.04.001
- By:
- Publication type:
- Article
A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2011, v. 10, n. 3, p. 210, doi. 10.1016/j.clcc.2011.03.018
- By:
- Publication type:
- Article